immediapress
comunicato stampa
Lupin Announces Presentation of Phase 1 Data on LNP3693 (STING agonist) at the ESMO Congress 2025
MUMBAI, India and NAPLES, Fla. and BERLIN, Oct. 13, 2025 /PRNewswire/ -- Global pharma major Lupin Limited (Lupin) (BSE: 500257) (NSE: LUPIN) (REUTERS: LUPIN.BO) (BLOOMBERG: LPCIN) will present data from its Phase 1a clinical trial evaluating LNP3693, a STING agonist, at the ESMO Congress in Berlin, ...
